New hope for tough blood disorder: drug boosts blood cell production
NCT ID NCT03988608
First seen Jan 09, 2026 · Last updated May 24, 2026 · Updated 22 times
Summary
This study tested a drug called eltrombopag in 20 Chinese adults with severe aplastic anemia, a rare condition where the bone marrow stops making enough blood cells. Participants had not improved after standard treatments. The drug was given daily for up to a year, with the dose adjusted based on platelet counts. The main goal was to see if blood cell levels improved after 6 months.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for APLASTIC ANEMIA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Novartis Investigative Site
Nanjing, Jiangsu, 210000, China
-
Novartis Investigative Site
Nanchang, Jiangxi, 330006, China
-
Novartis Investigative Site
Chengdu, Sichuan, 610041, China
-
Novartis Investigative Site
Tianjin, 300020, China
-
Novartis Investigative Site
Tianjin, 300052, China
Conditions
Explore the condition pages connected to this study.